EGFR in-frame deletions in exon 19 are the most prevalent of EGFR kinase domain mutations accounting for 45% of EGFR mutations in NSCLC, followed by the L858R missense mutation in exon 21, which accounts for approximately 40–45% of EGFR kinase domain mutations (Sharma et al., 2007). This evidence concerns the gene EGFR and non-small cell lung carcinoma.